期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 23, 期 21, 页码 -出版社
MDPI
DOI: 10.3390/ijms232112842
关键词
pafolacianine; intraoperative; tumor detection; folate receptor; fluorescent imaging; near-infrared spectrum
资金
- Romanian Ministry of Education and Research, CNCSUEFISCDI within PNCDI III [PN-III-P4-ID-PCE-2020-2027]
- Romanian Ministry of Education and Research, CNCS-UEFISCDI [PN-III-P4-PCE-2021-1680]
- Ministry of Research, Innovation and Digitization in Romania, under Program 1: The Improvement of the National System of Research and Development, Subprogram 1.2: Institutional Excellence-Projects of Excellence Funding in RDI [31PFE/30.12.2021]
Cancer is a leading cause of death globally, and surgery is the most effective method for removing malignant tissue. However, incomplete tumor resection often leads to relapse. To address this, pafolacianine, an intraoperative near-infrared imaging technology, has been approved by the FDA for detecting cancer during surgery. Studies have shown positive effects of pafolacianine in various malignancies.
Cancer is a leading cause of death worldwide, with increasing numbers of new cases each year. For the vast majority of cancer patients, surgery is the most effective procedure for the complete removal of the malignant tissue. However, relapse due to the incomplete resection of the tumor occurs very often, as the surgeon must rely primarily on visual and tactile feedback. Intraoperative near-infrared imaging with pafolacianine is a newly developed technology designed for cancer detection during surgery, which has been proven to show excellent results in terms of safety and efficacy. Therefore, pafolacianine was approved by the U.S. Food and Drug Administration (FDA) on 29 November 2021, as an additional approach that can be used to identify malignant lesions and to ensure the total resection of the tumors in ovarian cancer patients. Currently, various studies have demonstrated the positive effects of pafolacianine's use in a wide variety of other malignancies, with promising results expected in further research. This review focuses on the applications of the FDA-approved pafolacianine for the accurate intraoperative detection of malignant tissues. The cancer-targeting fluorescent ligands can shift the paradigm of surgical oncology by enabling the visualization of cancer lesions that are difficult to detect by inspection or palpation. The enhanced detection and removal of hard-to-detect cancer tissues during surgery will lead to remarkable outcomes for cancer patients and society, specifically by decreasing the cancer relapse rate, increasing the life expectancy and quality of life, and decreasing future rates of hospitalization, interventions, and costs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据